Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||Selinexor||Phase II||Actionable||In a Phase II trial, Selinexor demonstrated preliminary efficacy and poor toxicity profile in patients with abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer, resulted in partial response in 25% (2/8) and stable disease in 50% (4/8) of evaluable patients (PMID: 29487219).||29487219|